




To the Editor - Inositol-requiring enzyme 1 (IRE-1) is a central regulator of the unfolded protein 5 
response (UPR), and inhibiting its activity is likely to be of benefit for treating diseases related to 6 
proteostasis. Hetz et al. recently published a Review Article in Nature Chemical Biology 7 
exploring pharmacological targeting of the UPR for disease intervention1, in which they 8 
discussed the efficacy of the IRE-1 inhibitor B-I09 to induce leukemic regression without causing 9 
systemic toxicity in mouse models. They also pointed out a caveat that high concentrations of B-10 
I09 were administered frequently using 100% DMSO as a carrier and suggested that this 11 
reduces the translational potential of B-I09. Representing the team leading to the development 12 
and optimization of B-109 for clinical use, we believe that some of the features of the compound 13 
and the characterization of its translational potential require clarification. 14 
B-I09 was developed as a prodrug to target the RNase activity of IRE-1, leading to the15 
suppressed expression of XBP-1s2. We have used chemical synthesis to tune prodrug stability 16 
within a series of B-I09 analogues and achieve spatiotemporal control of inhibitory activity3. 17 
Studies using B-I09 have been instrumental in validating the IRE-1/XBP-1 pathway as a 18 
therapeutic target in diseases. For instance, pharmacological inhibition of XBP-1s using B-I09 19 
phenocopies genetic deletion of XBP-1s in mouse models of chronic lymphocytic leukemia, 20 
Burkitt’s lymphoma and chronic graft-versus-host disease (cGVHD)2, 4, 5. As demonstrated in 21 
ERAI reporter mice, B-I09 effectively blocks the RNase activity of IRE-1 in dendritic cells6. To 22 
the best of our knowledge, B-I09 is the only IRE-1/XBP-1 inhibitor for which published 23 
pharmacokinetic data has guided dosing in mice2. The translational potential of B-I09 is 24 
highlighted by consistent results in suppression of XBP-1s in targeted cells and amelioration of 25 
diseased conditions in various preclinical mouse models2, 4, 5, 7, 8. Importantly, B-I09 appears to 26 
impose no systemic toxicity in treated mice as documented in several preclinical studies2, 4, 5, 7, 8. 27 
Relative to other known inhibitors of IRE-1, B-I09 has demonstrated remarkable efficacy in 28 
multiple preclinical animal models and is well-tolerated in vivo. For these reasons, we believe 29 
that B-I09 has outstanding potential for translational application.  30 
CI statement: All authors declare no competing financial interests. J.R.D. and C.C.A.H. are 31 
named inventors of B-I09 and its analogues (Patent # US10,323,013). 32 
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